Rapid Publication

The Gene INPPL1, Encoding the Lipid Phosphatase SHIP2, Is a Candidate for Type 2 Diabetes In Rat and Man

Evelyne Marion,1 Pamela Jane Kaisaki,2 Valérie Pouillon,1 Cyril Gueydan,3 Jonathan C. Levy,4 André Bodson,5 Georges Krzentowski,5 Jean-Claude Daubresse,6 Jean Mockel,7 Jens Behrends,8 Geneviève Servais,9 Claude Szpirer,10 Véronique Kruyts,10 Dominique Gauguier,2 and Stéphane Schurmans1

Genetic susceptibility to type 2 diabetes involves many genes, most of which are still unknown. The lipid phosphatase SHIP2 is a potent negative regulator of insulin signaling and sensitivity in vivo and is thus a good candidate gene. Here we report the presence of SHIP2 gene mutations associated with type 2 diabetes in rats and humans. The R1142C mutation specifically identified in Goto-Kakizaki (GK) and spontaneously hypertensive rat strains disrupts a potential class II ligand for Src homology (SH)-3 domain and slightly impairs insulin signaling in cell culture. In humans, a deletion identified in the SHIP2 3′ untranslated region (UTR) of type 2 diabetic subjects includes a motif implicated in the control of protein synthesis. In cell culture, the deletion results in reporter messenger RNA and protein overexpression. Finally, genotyping of a cohort of type 2 diabetic and control subjects showed a significant association between the deletion and type 2 diabetes. Altogether, our results show that mutations in the SHIP2 gene contribute to the genetic susceptibility to type 2 diabetes in rats and humans. Diabetes 51:2012–2017, 2002

RESEARCH DESIGN AND METHODS

Localization of the SHIP2 gene on rat chromosomes. Fluorescent in situ hybridization and radiation hybrids mapping were performed as described (6). The following forward and reverse primers were used to amplify a 140-bp DNA fragment of the rat SHIP2 gene from hybrid DNA: 5′-CCAGGGGTTGAAAGTTTTGAG-3′ and 5′-CCGACCTGTGGCCCTAAGG-3′. SHIP2 gene amplification and sequencing in humans and rats. Consent was obtained from all subjects after the nature of the procedure was explained, and the investigation was conducted according to the principles expressed in the Declaration of Helsinki. All diabetic subjects were >35 years of age at diagnosis and met the World Health Organization’s criteria defining diabetes status. The control subjects were randomly and anonymously chosen in a DNA library isolated from a large population of women consulting for a genetic diagnosis of mutation in the CFTR gene. The SHIP2 cDNA and gene sequences were obtained after PCR amplification. The sequencing products were run on an Applied Biosystem sequencer.

CHO-IR transfection, Akt/protein kinase B, and mitogen-activated protein kinase activities. CHO cells expressing the human insulin receptor were transfected as described (5), with the pcDNA3 vector (Invitrogen) or with the same vector containing either the wild-type or the R1142C-mutated hemagglutinin A (HA)-tagged SHIP2 cDNA (nucleotides 264–4360 from AF162781). After 2 days, cells were stimulated with 10 nmol/l insulin during 2 min and then lysed. The supernatant was assayed for Akt/protein kinase B, and mitogen-activated protein kinase activities. Each activity is calculated from triplicate ± SE.

Rat L6 myoblast and hukam 293 embryonic kidney cell transfection. Rat, mouse, simian virus 40 (SV40), and human 3′UTR were amplified by PCR and subcloned in pGEM-T easy. A DNA fragment containing the SV40 promoter and luciferase cDNA was excised from the pGL3 vector and introduced into the above plasmids. Each plasmid (0.8 µg/10 cm2) was co-transfected in triplicate with 0.2 µg PSV-β-galactosidase transfection efficiency plasmid.

From 1IRIBHM (Institut de Recherches en Biologie Humaine et Moléculaire), IBMM (Institut de Biologie et de Médecine Moléculaires), ULB (Université Libre de Bruxelles), Gosselies, Belgium; the 2Wellcome Trust Centre for Human Genetics, University of Oxford, Headington, U.K.; the 3Laboratoire de Chimie Biologique, IBMM, ULB, Gosselies, Belgium; 4Diabetes Research Laboratories, University of Oxford, Headington, U.K.; the 5Department of Internal Medicine, Endocrinology-Diabetology, C.H.U. (Centre Hospitalier Universitaire) de Charleroi, site de Junet, Junet, Belgium; the 6Department of Internal Medicine, Endocrinology-Diabetology, C.H.U. de Charleroi, Charleroi, Belgium; the 7Department of Endocrinology, Hospital Erasme, ULB, Brussels, Belgium; the 8Department of Clinical Endocrinology, Medical School Hannover, Germany; the 9Department of Immunology, C.H.U. Brugmann-Huderz, ULB, Brussels, Belgium; and 10Laboratoire de Biologie du Développement, IBMM, ULB, Gosselies, Belgium.

Address correspondence and reprint requests to Stéphane Schurmans, IRIBHM-IBMM-ULB, rue des Professeurs Jeener et Brachtel 12, 4041 Gosselies, Belgium. E-mail: sschurma@ulb.ac.be.

After 24 h (human 293 cells) or 48 h (rat L6 myoblasts), the cells were lysed and processed either for luciferase activity according to manufacturer’s instructions (Promega) or for total RNA extraction. The amount of β-galactosidase present in the lysate was determined by enzyme-linked immunosorbent assay (Boehringer Mannheim). Total RNA (1 µg/lane) was loaded on a 1% agarose gel and transferred to a nylon membrane. A 1.6-kb fragment of the luciferase cDNA excised from the pGL3 vector was used as a radiolabeled probe. Quantification of the signals was performed on a phosphorimager.

RESULTS AND DISCUSSION
We first localized the SHIP2 gene on rat chromosomes because chromosomal regions suspected to contain one or several genes predisposing to type 2 diabetes or insulin resistance have been identified using rat polygenic models (7–9). Fluorescent in situ hybridization (FISH) and radiation hybrid mapping revealed that the rat SHIP2 gene is located on the long arm of rat chromosome 1.
TABLE 1
cDNA sequence analysis around amino acid 1142 (SHIP2) or the corresponding SHIP1 cDNA region in various species

<table>
<thead>
<tr>
<th>Name</th>
<th>Accession number</th>
<th>1142</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class II ligand consensus</td>
<td></td>
<td>PXXPX R</td>
</tr>
<tr>
<td>Rat SHIP2</td>
<td>AB011439</td>
<td>P-GPG R</td>
</tr>
<tr>
<td>Rat SHIP2</td>
<td>AB035794</td>
<td>P-GPG R</td>
</tr>
<tr>
<td>Brown-Norway rat SHIP2*</td>
<td></td>
<td>P-GPG R</td>
</tr>
<tr>
<td>Zucker-Fatty rat SHIP2</td>
<td></td>
<td>P-GPG C</td>
</tr>
<tr>
<td>Goto-Kakizaki rat SHIP2</td>
<td></td>
<td>P-GPG C</td>
</tr>
<tr>
<td>SHR rat SHIP2§</td>
<td></td>
<td>P-GPG C</td>
</tr>
<tr>
<td>Mouse SHIP2</td>
<td>AF162781</td>
<td>P-GPG R</td>
</tr>
<tr>
<td>Human SHIP2</td>
<td>Y14385</td>
<td>PAGPA R</td>
</tr>
<tr>
<td>Rat SHIP1</td>
<td>U55192</td>
<td>PVKPS R</td>
</tr>
<tr>
<td>Mouse SHIP1</td>
<td>NM010566</td>
<td>PVKPS R</td>
</tr>
<tr>
<td>Human SHIP1</td>
<td>U57650</td>
<td>PIKPS R</td>
</tr>
</tbody>
</table>

*As F344, COP, WF, WKY, WKY Leicester, SD, PD, Buffalo, Mib, LEW, BKI, BDII, LE, MNS, SS/jr, SR/jr and SPRD rat strains; §includes SHR/le, SHRSP/gla, and the original strain SHRSP/izm.

Localized on the long arm of chromosome 1, at q33-36, between markers D1Got150 and D1Mit4 (Fig. 1A). It co-localizes with Nidd/gkl quantitative trait locus (QTL), a QTL for glucose homeostasis identified in the diabetic GK rat strain (8). SHIP2 mRNA expression was investigated by Northern blotting in skeletal muscles from GK rats, but no significant difference was observed when compared with the diabetic and obese Zucker-fatty or control Brown-Norway rat SHIP2.

To test the effects of the R1142C mutation on SHIP2 function in insulin signaling, wild-type and mutated SHIP2 cDNAs were introduced in CHO cells expressing the human insulin receptor (CHO-IR) by transfection. Because PKB/Akt and MAP kinase (ERK-2) are two signaling molecules downstream of the insulin receptor, their activities were analyzed in CHO-IR cells after hormone stimulation. Expression of wild-type or mutated SHIP2 cDNAs in CHO-IR cells resulted in decreased PKB and MAP kinase activities after insulin stimulation, as compared with vector-transfected CHO-IR cells (Fig. 1C). However, a slightly but significantly more important decrease was observed when the mutated protein was expressed.

Altogether, these data indicate that the R1142C mutation specifically identified in GK and spontaneously hypertensive (SHR) rats slightly impairs insulin signaling and may contribute to the genetic predisposition to type 2 diabetes and/or insulin resistance in these rat strains.

The presence of a relevant mutation associated with diabetes and/or insulin-resistance in two rat strains led us to investigate the human SHIP2 gene. The SHIP2 cDNA from eight unrelated Caucasian subjects with type 2 diabetes and from four control subjects of the same origin was sequenced. No difference was detected in the SHIP2 coding region. To our surprise, one of the type 2 diabetic subjects (SMH10), but none of the control subjects, exhibited a heterozygotic deletion in the proximal part of the SHIP2 3’UTR (Fig. 2A). The 16-bp deleted sequence contains an ATTGA pentamer potentially belonging to an adenylate/uridylate-rich element (ARE) (Fig. 2B and C). AREs are conserved sequence elements implicated in the regulation of messenger RNA (mRNA) stability and translation efficiency (16,17). Sequence comparison between mouse, rat, and human SHIP2 3’UTR identified ATTGA pentamers or related sequences, like ATTTGA hexamer, embedded in very conserved regions (Fig. 2B and C). In the rat and mouse 3’UTR, two pentamers and one hexamer sequences were detected (Fig. 2B). In man, a 16-bp fragment containing the first ATTGA pentamer was exactly duplicated, as compared with rat and mouse, and a total of three pentamers and one hexamer were detected (Fig. 2B and C). In addition, a very conserved thymidylate was mutated in adenylate in the hexamer, potentially affecting its function (Fig. 2B). To test the capacity of the SHIP2 rat, mouse, and human 3’UTR to regulate protein expression, plasmids containing the SV40 promoter followed by the luciferase cDNA and one of the 3’UTR described above were constructed and introduced in rat L6 myoblasts by transfection (Fig. 3A). The SV40 3’UTR was used as control, because it does not contain any AREs. The presence of the SV40 3’UTR downstream of the luciferase cDNA resulted in a 10- to 70-fold higher luciferase activity, as compared with SHIP2 rat, mouse, and human 3’UTR. In rat L6 cells, the lowest luciferase activity was detected with the rat 3’UTR, followed by the mouse and human 3’UTR. A 4.5- and 7.7-fold increase in luciferase activity were respectively observed with these 3’UTR, as compared with the rat 3’UTR (Fig. 3A). Altogether, these results suggest that the AREs present in the SHIP2 3’UTR are functional and lead to decreased expression of the reporter gene. Thus, mutations in the SHIP2 3’UTR sequence could affect ARE function, SHIP2 expression, and insulin sensitivity, contributing to type 2 diabetes patho-
FIG. 2. The 3'UTR of the SHIP2 gene: structure and mutations. A: The Δ16-bp mutation found in the SHIP2 3'UTR from the SMH10 subject: sequence of the PCR product amplified from SMH10 cDNA (above), and sequences of the wild-type (middle) and the Δ16-bp mutant (below) after subcloning. B and C: Structure of the SHIP2 3'UTR: number and location of ATTTA pentamers and ATTTTA hexamers in man, rat, and mouse. Definition of the three mutations (Δ4bp, G/A substitution, and Δ16 bp) found in the SHIP2 3'UTR, and location of the regions with a high percentage of identity between mouse, rat, and man.
SHIP2 MUTATIONS IN TYPE 2 DIABETES

FIG. 3. Effects of the wild-type and the Δ16 SHIP2 3′ UTRs on luciferase reporter gene expression. Transfection efficiencies were assessed by β-galactosidase protein quantification, and luciferase reporter gene expression was corrected accordingly. Differences in transfection efficiencies between the tested plasmids of the same experiment were always <10%. A: Luciferase expression in rat L6 cells transfected with a plasmid vector containing the 3′ UTR from SV40, rat, mouse, or human SHIP2 gene. Results are the means ± SE and are representative of three separate experiments performed in triplicate. *P < 0.05; **P < 0.005 (Student’s t test). B: Luciferase expression in human 293 cells transfected with a plasmid vector containing either the wild-type or the Δ16-bp mutation. Results are the means ± SE and are representative of four separate experiments performed in triplicate. C: Total RNA isolated from human 293 cells transfected with the empty plasmid vector (0) or a plasmid vector containing either the wild-type (WT) or the Δ16-bp mutated (Δ16) SHIP2 was analyzed with a luciferase or an actin probe. Densitometric analysis of the signals was performed with a phosphorimager. Results are the means ± SE.

genesis. To test the capacity of the mutated 3′ UTR found in SMH10 type 2 diabetic subjects to regulate the gene reporter expression, the wild-type and Δ16 SHIP2 3′ UTR were placed downstream of the luciferase cDNA, and the plasmids were introduced in human 293 cells by transfection (Fig. 3B). The presence of the Δ16 mutation resulted in a fourfold increase in luciferase activity (range 2.8–5.8; mean 4.0; n = 4; P < 10⁻⁴ by Student’s t test), as compared with the wild-type 3′ UTR. The increased luciferase activity observed with the Δ16 mutant was not dependent on the presence of insulin: a similar ratio of the luciferase activities found with the wild-type and the Δ16 SHIP2 3′ UTR was observed when human 293 cells were cultured with or without 100 nmol/l insulin (data not shown). The increased luciferase activity observed with the Δ16 mutant was associated with an equal increase in the luciferase mRNA level (Fig. 3C). Indeed, quantification of the luciferase mRNA signals found in transfected human 293 cells revealed a 4.5-fold increased level with the Δ16 mutant, as compared with the wild-type 3′ UTR (range 3.4–5.1; mean 4.3; n = 3; P < 0.02 by Student’s t test). Our results suggest that the Δ16 deletion identified in the SHIP2 3′ UTR of one type 2 diabetic subject results in decreased ARE function and increased mRNA and protein expressions, which may result in decreased insulin signaling, i.e., insulin resistance in vivo. We next determined the accurate frequency of the Δ16 mutated allele in Caucasian populations of type 2 diabetic and control subjects. DNA samples from type 2 diabetic subjects originating from the U.K. (n = 246) and Belgium (n = 169), as well as from anonymous healthy individuals collected by the Genetics Department of the Erasme Hospital in Brussels (n = 567), were included in the experiment. A total of 9 Δ16 mutations (5 in the Belgian cohort and 4 in the English cohort) were identified in 415 unrelated type 2 diabetic subjects (frequency 2.16%), whereas only 3 mutations were identified in 567 control subjects (frequency 0.52%). Statistical analysis using the Pearson χ² test revealed a significant association between the Δ16 mutation and type 2 diabetes (P = 0.021). The nine diabetic subjects with a Δ16 mutation had a typical type 2 diabetes history: the age at diagnosis was always >40 years (range 44–67) and their treatment did not required insulin injections. BMI ranged from 23.9 to 38.1 kg/m². Five of the nine diabetic subjects had a familial history of type 2 diabetes, and seven of nine were hypertensive.

Sequence analysis identified two other mutations close to the same region in the cohort of diabetic subjects (Fig. 2C). A single nucleotide substitution (A to G) in the first ATTTA pentamer and a 4-base-pair deletion (Δ4) located
upstream of the same pentamer were present in three and one type 2 diabetic subjects (n = 415), respectively, but not in any of the control subjects tested (n = 567). Both mutations were associated with a slightly increased luciferase gene reporter expression in 293 cells (data not shown).

Together, these present data indicate that a 16-bp deletion including a potential ARE in the human SHIP2 3’UTR is significantly associated with type 2 diabetes, results in increased expression of reporter mRNA and protein in vitro, and presumably increased SHIP2 expression in vivo, leading to decreased insulin sensitivity. Thus, as in rats, SHIP2 is a candidate gene contributing to the genetic susceptibility of type 2 diabetes, a frequent metabolic disease characterized by the presence of insulin resistance and/or defects in insulin production/secretion by pancreatic β-cells. However, more detailed analysis, like family segregation of the present mutations, mutation frequency in larger diabetic cohorts from Caucasian and other ethnic groups, as well as SHIP2 protein quantification after muscle biopsy, are required to definitively validate SHIP2 as a predisposing gene for type 2 diabetes.

ACKNOWLEDGMENTS

This work was supported by the Fonds de la Recherche Scientifique Méédicale de Belgique, Interreg II (cofincanced by the Région Wallonne and the European Commission, FEDER), The Banque Nationale de Belgique, Action de Recherche Concertée, and a grant from The Free University of Brussels (to S.S.), and by the Wellcome Trust. D.G. holds a Wellcome senior fellowship in basic biomedical science. S.S. and C.S. are respectively Maitre and Directeur de Recherche of the Belgian FNRS.

We thank all type 2 diabetic subjects for their participation in the study; P. Shepherd for CHO-IR cells; C. Erneux, L. Hue, M. Latrop, and F. Libert for discussions; W. Malaisse for GK rats; P. Van Vooren for technical assistance; and D. Eggerickx and J. Dewulf for help with the Belgian diabetic cohort study.

The U.K. collection of diabetic patients was developed by the late Professor R. Turner.

REFERENCES